Merck Provides Update on KEYNOTE-240, a Phase 3 Study of KEYTRUDA (pembrolizumab) in Previously Treated Patients with Advanced Hepatocellular Carcinoma

- solid tumors that have progressed following prior treatment and who have no satisfactory alternative treatment options, or
- colorectal cancer that has progressed following treatment with fluoropyrimidine, oxaliplatin, and irinotecan.